An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients with Parathyroid Carcinoma or Primary Hyperparathyroidism who are Unable to Undergo Parathyroidectomy or Relapse after Parathyroidectomy

Trial Profile

An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients with Parathyroid Carcinoma or Primary Hyperparathyroidism who are Unable to Undergo Parathyroidectomy or Relapse after Parathyroidectomy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Evocalcet (Primary)
  • Indications Primary hyperparathyroidism
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 12 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top